biostudies-literatureKishan AUNCI NIH HHSe2115312https://www.ebi.ac.uk/biostudies/studies/S-EPMC8251338biostudies-literatureUnknown4(7)<h4>Importance</h4>The optimal management strategy for high-risk prostate cancer and additional adverse clinicopathologic features remains unknown.<h4>Objective</h4>To compare clinical outcomes among patients with high-risk prostate cancer after definitive treatment.<h4>Design, setting, and participants</h4>This retrospective cohort study included patients with high-risk prostate cancer (as defined by the National Comprehensive Cancer Network [NCCN]) and at least 1 adverse clinicopathologic feature (defined as any primary Gleason pattern 5 on biopsy, clinical T3b-4 disease, ≥50% cores with biopsy results positive for prostate cancer, or NCCN ≥2 high-risk features) treated between 2000 and 2014 at 16 tertiary centers. Data were analyzed in November 2020.<h4>Exposures</h4>Radical prostatectoJAMA network openComparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.PMC8251338P50 CA211015Horwitz EMDess RTMoran BJBhat PKrauss DJRoss AEJuarez JESchwen ZMartin SKlein EAReddy CHuland HAlam RTilki DKarnes RJKupelian PADemanes DJSong DYTendulkar RDCiezki JPTosoian JJChong NPilar AFiano RD'Amico AVMotterle GDeville CKishan AUDavis BJSteinberg MLElashoff DLevin-Epstein RChang AJPisansky TMBraccioforte MChoo RMcNutt TWedde TBRettig MBRomero TSpratt DETran PTMartinez-Monge RMerrick GSTward JDDeWeese TLAbu-Isa EIBerlin AStish BJReiter REWong JKNickols NGTrock BJBoutros PCGreco SShabsovich DStock RGLilleby WAfalseComparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.<h4>Importance</h4>The optimal management strategy for high-risk prostate cancer and additional adverse clinicopathologic features remains unknown.<h4>Objective</h4>To compare clinical outcomes among patients with high-risk prostate cancer after definitive treatment.<h4>Design, setting, and participants</h4>This retrospective cohort study included patients with high-risk prostate cancer (as defined by the National Comprehensive Cancer Network [NCCN]) and at least 1 adverse clinicopathologic feature (defined as any primary Gleason pattern 5 on biopsy, clinical T3b-4 disease, ≥50% cores with biopsy results positive for prostate cancer, or NCCN ≥2 high-risk features) treated between 2000 and 2014 at 16 tertiary centers. Data were analyzed in November 2020.<h4>Exposures</h4>Radical prostatecto2021-01-01T00:00:00Z2021 Jul2025-05-18T11:05:01.782Z2025-05-18T11:05:01.782ZS-EPMC82513383419671510.1001/jamanetworkopen.2021.15312